376 related articles for article (PubMed ID: 32780245)
1. Molecular mediators of peritoneal metastasis in pancreatic cancer.
Avula LR; Hagerty B; Alewine C
Cancer Metastasis Rev; 2020 Dec; 39(4):1223-1243. PubMed ID: 32780245
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Alterations in Pancreatic Cancer Metastasis.
Wang SS; Xu J; Ji KY; Hwang CI
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439749
[TBL] [Abstract][Full Text] [Related]
3. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.
Hessmann E; Schneider G; Ellenrieder V; Siveke JT
Oncogene; 2016 Mar; 35(13):1609-18. PubMed ID: 26119937
[TBL] [Abstract][Full Text] [Related]
4. EIPL (extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer.
Yamamoto K; Shimada S; Hirota M; Yagi Y; Matsuda M; Baba H
Int J Oncol; 2005 Nov; 27(5):1321-8. PubMed ID: 16211228
[TBL] [Abstract][Full Text] [Related]
5. Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinical Trial.
Yonkus JA; Alva-Ruiz R; Abdelrahman AM; Leiting JL; Schneider AR; Grotz TE; Cleary SP; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Truty MJ
J Am Coll Surg; 2021 Jul; 233(1):73-80.e1. PubMed ID: 34022414
[TBL] [Abstract][Full Text] [Related]
6. Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?
Chandana S; Mahadevan D
Expert Rev Mol Med; 2009 Nov; 11():e34. PubMed ID: 19919723
[TBL] [Abstract][Full Text] [Related]
7. [Pathogenesis of the ductal pancreatic adenocarcinoma: implications for future therapies?].
Schneider G; Schmid RM
Internist (Berl); 2005 Feb; 46(2):157-65. PubMed ID: 15655682
[TBL] [Abstract][Full Text] [Related]
8. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
Dunne RF; Hezel AF
Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
[TBL] [Abstract][Full Text] [Related]
9. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas.
Hidalgo M; Von Hoff DD
Clin Cancer Res; 2012 Aug; 18(16):4249-56. PubMed ID: 22896691
[TBL] [Abstract][Full Text] [Related]
10. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.
Orozco CA; Martinez-Bosch N; Guerrero PE; Vinaixa J; Dalotto-Moreno T; Iglesias M; Moreno M; Djurec M; Poirier F; Gabius HJ; Fernandez-Zapico ME; Hwang RF; Guerra C; Rabinovich GA; Navarro P
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3769-E3778. PubMed ID: 29615514
[TBL] [Abstract][Full Text] [Related]
11. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
[TBL] [Abstract][Full Text] [Related]
12. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic biomarkers: could they be the answer?
Lamarca A; Feliu J
World J Gastroenterol; 2014 Jun; 20(24):7819-29. PubMed ID: 24976720
[TBL] [Abstract][Full Text] [Related]
14. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
Knudsen ES; O'Reilly EM; Brody JR; Witkiewicz AK
Gastroenterology; 2016 Jan; 150(1):48-63. PubMed ID: 26385075
[TBL] [Abstract][Full Text] [Related]
15. Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Neesse A; Bauer CA; Öhlund D; Lauth M; Buchholz M; Michl P; Tuveson DA; Gress TM
Gut; 2019 Jan; 68(1):159-171. PubMed ID: 30177543
[TBL] [Abstract][Full Text] [Related]
16. Organoid models for translational pancreatic cancer research.
Tiriac H; Plenker D; Baker LA; Tuveson DA
Curr Opin Genet Dev; 2019 Feb; 54():7-11. PubMed ID: 30844513
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Implications of Wingless/int1 (WNT) Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
Nakamoto M; Hisaoka M
J UOEH; 2016 Mar; 38(1):1-8. PubMed ID: 26972939
[TBL] [Abstract][Full Text] [Related]
18. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
Satoi S; Fujii T; Yanagimoto H; Motoi F; Kurata M; Takahara N; Yamada S; Yamamoto T; Mizuma M; Honda G; Isayama H; Unno M; Kodera Y; Ishigami H; Kon M
Ann Surg; 2017 Feb; 265(2):397-401. PubMed ID: 28059968
[TBL] [Abstract][Full Text] [Related]
19. Genomics of pancreatic ductal adenocarcinoma.
Pilarsky C; Grutzmann R
Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer.
Vincent A; Herman J; Schulick R; Hruban RH; Goggins M
Lancet; 2011 Aug; 378(9791):607-20. PubMed ID: 21620466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
